TP53 and acute myeloid leukemia: Such AML category is characterized by high-risk cytogenetics [i.e., complex and/or monosomal karyotypes, chromosomes 3, 5, 7, and 17 aberrations) and/or by specific genetic signatures (including mutations in TP53, RUNX1, ASXL1, and FLT3 genes (2)] that confer an aggressive phenotype and often chemoresistance.